Seres Therapeutics(MCRB)2025-03-13 11:07Financial Position - As of December 31, 2024, Seres Therapeutics had preliminary cash and cash equivalents of 75 million from Nestlé Health Science in January and July 2025 related to the VOWST sale, which will support operations into the first quarter of 2026[8]. - The preliminary financial results remain subject to change based on the completion of closing and review procedures[7]. - The company emphasizes that the estimated preliminary financial results have not been audited or reviewed by its independent registered public accounting firm[11]. - Forward-looking statements regarding financial performance and clinical studies are subject to risks and uncertainties that may affect actual results[10]. Clinical Development - SER-155 demonstrated a statistically significant decrease in fecal albumin, indicating improved epithelial barrier integrity in patients undergoing allo-HSCT[6]. - The FDA granted Breakthrough Therapy designation to SER-155 for the reduction of bloodstream infections in adults undergoing allo-HSCT in December 2024[6]. - The company plans to submit a Briefing Book to the FDA regarding a potential next registrational study of SER-155 in allo-HSCT, expecting feedback in Q1 2025[6]. - SER-155's biomarker data supports its potential in reducing bloodstream infections by promoting epithelial barrier integrity[6]. - The company is focused on clinical development plans and anticipates future market potential for SER-155 and other product candidates[9].